NASDAQ · STOCK
Boston Scientific
$46.73
52W $42.20 – $109.50
57/100
$69.46B
18.8
0.58
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BSX Bullish or Bearish?
Bullish.
Innellis AI committee rates Boston Scientific (BSX) Buy with a composite score of 57/100
, based on 6 analysts with 83% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.11 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.89 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — eps growing 74.7% yoy — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- EPS growing 74.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 5.8x prices in significant intangible value — Value
- Negative filing: Costs associated with exit or disposal (restructuring) (4d ago) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
57/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 38%
of 93 Healthcare peers
Value Analyst
neutral
53
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 5.8x prices in significant intangible value
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 74.7% YoY
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
48
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
− Negative filing: Costs associated with exit or disposal (restructuring) (4d ago)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 57.8 to 56.9.
- Conviction changed from moderate to high.
- Committee agreement increased notably from 67% to 83%.
- New bearish signals: 3 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bearish signal(s).
- Portfolio Manager: +2 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
72.2
Overbought
MACD Histogram
0.559
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$44.35
Resistance
$47.49
Bollinger %B
0.96
Inside Bands
Price vs Moving Averages
EMA 9
$45.40
Above
EMA 21
$45.09
Above
EMA 50
$47.78
Below
EMA 200
$67.01
Below
Fundamental Analysis
Valuation
89
Growth
78
Profitability
1
Financial Health
96
Cash Flow
37
Valuation
P/E Ratio
18.8×
P/B Ratio
2.67×
PEG Ratio
0.41
Dividend Yield
0.00%
52W High
$109.50
52W Low
$42.20
Quality & Growth
ROE
11.9%
ROA
6.6%
Gross Margin
71.2%
Operating Margin
21.5%
Revenue Growth YoY
—
Debt / Equity
0.43
AI Fundamental Assessment
P/E ratio of 18.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.7x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 1.90 (healthy short-term liquidity); Debt-to-equity of 0.43; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (2.33); Most recent quarter beat estimates by 2.9%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +7.5% QoQ); Average YoY EPS growth of 14.7%; Analyst estimates rising over recent quarters
Get the Full BSX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →